Paliperidona Alter (Paliperidone Palmitate)

Paliperidona Alter is used in the management of schizophrenia, a chronic psychotic disorder that affects thought processes and perception.

• Schizophrenia: Reduces the frequency and severity of psychotic episodes and helps maintain functional stability.
• Schizoaffective disorder: Alleviates mood‑related symptoms while controlling psychosis.
• Maintenance therapy after acute stabilization: Provides sustained symptom control with monthly dosing, reducing the need for daily oral medication.

• Paliperidone palmitate is a long‑acting formulation of paliperidone, a dopamine‑D2 and serotonin‑5‑HT2A receptor antagonist. By blocking D2 receptors in mesolimbic pathways, it reduces dopaminergic over‑activity that underlies psychotic symptoms, while 5‑HT2A antagonism modulates serotonin activity, contributing to mood stabilization and lower risk of extrapyramidal side effects.

Paliperidona Alter may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects

• Injection site pain or erythema
• Headache
• Drowsiness or somnolence
• Weight gain
• Restlessness (akathisia)
• Nausea

Serious or Rare Side Effects

• Neuroleptic malignant syndrome
• Tardive dyskinesia
• Severe orthostatic hypotension
• Hyperglycaemia or new‑onset diabetes
• Seizures
• Elevated prolactin leading to galactorrhoea or menstrual disturbances

When prescribing Paliperidona Alter, clinicians should consider several safety aspects.

• Cardiovascular assessment: Evaluate for history of arrhythmias or QT prolongation.
• Metabolic monitoring: Check glucose and lipid levels periodically.
• Pregnancy and lactation: Use only if the benefit outweighs potential risk to the fetus or infant.
• Elderly patients: Start at the lowest effective dose and monitor for sedation.
• Concomitant CNS depressants: Use with caution due to additive sedative effects.
• Store at room temperature: keep in original container, protect from light and moisture.

Paliperidona Alter can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase paliperidone exposure and risk of toxicity.
• QT‑prolonging agents (e.g., quinidine, sotalol): Heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely):\n- CNS depressants (e.g., benzodiazepines, opioids): May enhance sedation and respiratory depression.

• Antihypertensive drugs: Potential additive hypotensive effect.
• Antidiabetic medications: May require dose adjustment due to altered glucose metabolism.